Today, modern HIV treatment is incredibly effective. For millions of people, antiretroviral therapy (ART) successfully suppresses the virus to undetectable levels. However, as clinicians and researchers, we face a hidden, ongoing battle.
Nearly half of all new HIV diagnoses happen in people with advanced disease. For these "late presenters," the virus has already caused severe damage to their immune systems. Even after starting medication and suppressing the virus, they often suffer from a dangerous "comorbidity gap." They face a much higher risk of heart disease, metabolic disorders, and accelerated aging compared to the general population.
This heightened risk is driven by a state of constant, chronic inflammation. We wanted to understand exactly why this happens—and more importantly, whether the specific HIV medications we prescribe can make a difference. The search for answers took us away from the blood, and into the gut.
The Root of the Problem: The "Leaky Gut"
The human digestive tract is much more than a place where food is processed; it is the largest immune organ in the body.
During the early, untreated stages of HIV, the virus aggressively attacks the gut. This damages the delicate lining of the intestines, creating a condition known as "leaky gut." When this barrier is broken, bacterial products escape from the intestines into the bloodstream, triggering a constant immune alarm.
At the same time, the rich community of microbes living in our intestines—the gut microbiome—is thrown into chaos. Helpful bacteria are depleted, and the ecosystem becomes severely unbalanced. We wanted to know: can starting HIV treatment actually reverse this severe gut damage? And does the type of drug matter?
A Two-Year Journey: The ADVANZ-4 Trial
To find out, we recruited 88 people newly diagnosed with advanced HIV. We randomly assigned them to start one of two standard daily treatments: one based on dolutegravir (an integrase inhibitor) and another based on darunavir/ritonavir (a protease inhibitor).
For nearly two years, we monitored their immune recovery and collected stool samples to track how their gut microbiomes changed over time. Collecting, preserving, and analyzing DNA from stool samples over two years is a massive logistical challenge. Many of our patients were dealing with severe infections at the start of the trial, and their willingness to contribute to this research, visit after visit, was the true foundation of this study.
The Discovery: A Tale of Two Therapies
When we analyzed the data, the results were striking. Clinically, both drugs did an excellent job: patients in both groups successfully suppressed the HIV virus and saw their circulating immune cells recover. But inside the gut ecosystem, their paths diverged entirely.
For patients taking darunavir/ritonavir, the gut microbiome remained stuck in an unhealthy, chaotic state. Despite two full years of effective antiviral treatment, their microbial communities did not recover.
In stark contrast, patients taking dolutegravir experienced a profound healing of their gut ecosystems. Over the two years, their microbiomes became richer and more diverse. We saw the return of vital, cooperative microbes—like Methanobrevibacter smithii and Olsenella. In a healthy gut, these microbes work as a team to produce beneficial fatty acids that physically repair the intestinal lining and calm the immune system.
Crucially, this gut healing had a real-world impact. As the gut microbiomes of the patients on dolutegravir recovered, their blood tests showed significantly lower levels of systemic inflammation.
Healing the Ecosystem
This discovery changes how we think about HIV treatment for patients diagnosed late. It proves that not all therapies are equal when it comes to tissue-level healing. Dolutegravir didn't just stop the virus; it created an environment where the gut could physically repair itself, cooling down the chronic inflammation that drives long-term health problems.
Looking forward, this opens exciting new doors. If we can monitor a patient's gut recovery, we might be able to identify who needs extra help—like specific probiotics or dietary changes—to restore their internal ecosystem. By choosing the right tools, we can offer these patients not just a longer life, but a fundamentally healthier one.
A Dedication to the Scientist Behind the Data
Science is driven by data, but it is built by people. The extensive computational and ecological analysis required to make sense of this massive two-year dataset was the central pillar of the PhD thesis of our brilliant colleague and dear friend, Carlos Blázquez-Bondia. Tragically, Carlos, along with our esteemed clinical colleague Dr. Lluís Force Sanmartí, passed away before this manuscript could be completed.
We proudly dedicate this publication, and this post, to their memory. Carlos’s intellect, passion, and tireless hard work were the true scientific engines behind these discoveries. Bringing this multi-year project to the finish line is a celebration of his science.